Teva Pharmaceutical Industries Limited (NYSE:TEVA) 7th Annual Evercore ISI HealthCONx Healthcare Conference Call December 5, 2024 8:20 AM ET
Company Participants
Richard Francis – President and Chief Executive Officer
Eric Hughes – Executive Vice President, Global R&D and Chief Medical Officer
Conference Call Participants
Umer Raffat – Evercore ISI
Umer Raffat
Thank you, guys for being here. Super excited to have Teva management. We’re going to go a little past this 20 minutes, just because there’s a lot of topics of discussion. And for folks that are here, please let me know if you want to jump in with questions as well. You’re absolutely welcome to jump in with questions.
Richard, I’ll let you kick it off and we have a lot of topics to go through.
Richard Francis
Okay. Well, I’ll try and keep it brief. So, thanks Umer for having me. Appreciate people coming to listen.
So, I think there’s quite a bit to talk about Teva, which is nice. We launched the Pivot to Growth strategy two years ago, which laid out a clear framework of how we’re going to grow the company over multiple years. Four pillars. I will talk about those. How we’re going to drive our innovative portfolio in the market. How — with my help of Eric, who step up innovation and drive our pipeline through.
And the third pillar was to create generics powerhouse, and the fourth pillar was to make sure we focus the company, particularly the capital allocation. So, as I talk today with Umer yourselves, I’ll always refer back to those pillars, always refer back to the plan of what we’re executing. And I’d like to think that the last two years we’ve shown that what we say we do, we do and we execute really well. And I think we’ve changed the trajectory of the company. But that
Read the full article here
